Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Investing Activities (2019 - 2025)

BridgeBio Pharma's Cash from Investing Activities history spans 7 years, with the latest figure at -$14.4 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 343.44% year-over-year to -$14.4 million; the TTM value through Dec 2025 reached -$24.5 million, down 140.29%, while the annual FY2025 figure was -$24.5 million, 140.29% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$14.4 million at BridgeBio Pharma, down from $4.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $149.7 million in Q2 2022 and bottomed at -$282.1 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is $8.4 million (2023), against an average of $17.1 million.
  • The largest annual shift saw Cash from Investing Activities skyrocketed 32586.03% in 2022 before it plummeted 4804.55% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $21.8 million in 2021, then decreased by 17.59% to $18.0 million in 2022, then plummeted by 100.37% to -$66000.0 in 2023, then tumbled by 4804.55% to -$3.2 million in 2024, then plummeted by 343.44% to -$14.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Cash from Investing Activities are -$14.4 million (Q4 2025), $4.5 million (Q3 2025), and -$13.0 million (Q2 2025).